Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
TB-500 Compounding Legal Status: FDA Approval, Safety, and What Patients Need to Know At a glance FDA approval status / TB-500 has never been FDA-approved for any indication Drug classification / Synthetic peptide fragment of thymosin beta-4 Compounding route / Prepared by some 503A pharmacies under individual patient prescriptions FDA-approved labeling / None exists
10.3920/BM2016.0114 56 KarimiS.JonssonH.LundhT.RoosS
FOXO4-DRI enters senescent cells and competitively binds to p53 through its modified peptide sequence, displacing endogenous FOXO4 and freeing p53 to activate cell death pathways including BAX and PUMA
Additionally, it participates in bettering your immune system, tissue generation and development, enhances anticancer ability, maintains anti-ageing properties, and counterbalances free radicals
published databases are lacking
US$ 24.27
US$ 20.36
US$ 27.66
US$ 27.92
US$ 26.10
US$ 26.40
US$ 28.46
